Reproducibility of Low Galactomannan Enzyme Immunoassay Index Values Tested in Multiple Laboratories
Open Access
- 1 September 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (9) , 4796-4800
- https://doi.org/10.1128/jcm.43.9.4796-4800.2005
Abstract
The Platelia galactomannan enzyme immunoassay is a commercially available nonculture method for diagnosing invasive aspergillosis. Recently, steps have been taken to improve sensitivity; specifically, a low (0.5 to 0.7) galactomannan index (GMI) value to determine positivity has been validated by multiple groups. We evaluated the intra-assay and interassay reproducibility at low index levels using three different kit lots on three different days in three different microbiology laboratories. Clinical and spiked sera were blinded and sent with galactomannan enzyme immunoassay (EIA) kits to the participating laboratories. We also prospectively collected data on all galactomannan EIAs performed between 1 September 2003 and 21 July 2004 at the University of Washington Medical Center microbiology laboratory to assess reproducibility of clinical samples analyzed in “real time.” From the multilaboratory study, a total of 836 results were available for evaluation. Reproducibility was excellent between laboratories and on different days. Significant variability was seen between runs/lots, which may in part be associated with different threshold control values in different kits. Among the 1,410 clinical samples that were prospectively analyzed, 168 (90%) were confirmed to be positive on repeat testing (GMI, ≥0.5). Among the 19 (10.2%) initially positive samples not confirmed on repeat testing, the majority had a GMI at the threshold of the assay (between 0.5 and 0.7). Our findings suggest that the Platelia galactomannan immunoassay has good reproducibility. However, changes in GMI levels when different kit lots are used, and single samples with low-positive (GMI of 0.5 to 0.7) indices, should be interpreted with caution.Keywords
This publication has 18 references indexed in Scilit:
- Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme ImmunoassayClinical Infectious Diseases, 2005
- Prospective clinical evaluation of lower cut‐offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipientsBritish Journal of Haematology, 2004
- Detection of Galactomannan Antigenemia by Enzyme Immunoassay for the Diagnosis of Invasive Aspergillosis: Variables That Affect PerformanceThe Journal of Infectious Diseases, 2004
- Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive AspergillosisJournal of Clinical Microbiology, 2003
- Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factorsBlood, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Longitudinal Study of Bacterial, Viral, and Fungal Infections in Adult Recipients of Bone Marrow TransplantsClinical Infectious Diseases, 2001
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- Invasive Aspergillosis Disease Spectrum, Treatment Practices, and OutcomesMedicine, 2000
- Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipientsBone Marrow Transplantation, 1998